Nilotinib for Cytomegalovirus Prophylaxis and Treatment After Allogeneic Hematopoietic Stem Cell Transplantation

Exclusion Criteria

• •Patients with renal insufficiency: serum creatinine \> 2.5 mg/dL,
• •Patients with significant electrolyte deficiency after suitable supplement: \[K\] \<3.0mmol/L, \[Ca\]\< 2.0 mmol/L(corrected), or \[Mg\] \< 0.6 mmol/L.
• •Patients with hepatic dysfunction: alkaline phosphatase ≥2.5 times of the upper normal limit of the normal range (ULN); serum alanine or aspartate aminotransferase levels of \> 5 times ULN; a serum total bilirubin of \> 3 mg/dL
• •Patients with serum amylase and lipase \> 1.5 x ULN
• •Patients with history of HIV infection
• •Patients with unstable medical condition or any other history of serious/significant medical diseases deemed not appropriate to be included to this study as judged by investigators
• •Females patient who are pregnant or breast-feeding
• •Female patients of childbearing potential not using any reliable and appropriate contraception method(s)
• •Patients with life expectancy, as judged by the investigators, is less than 3 months
• •Patients with, as judged by the investigators, other contraindications of nilotinib administration, such as prolonged QTc, concurrent usage of drugs that possess possible severe drug-drug interactions with nilotinib, or had severe adverse effects in the previous exposure to nilotinib
• •Patients who cannot swallow capsules.
• •Patients who are unwilling or unable to give consent